BCG Vaccines Sales Market

BCG Vaccines Sales Market size was valued at USD 101.30 Million in 2024 and the total Global BCG Vaccines Sales revenue is expected to grow by 4.2% from 2025 to 2032, reaching nearly USD 140.78 Million

BCG Vaccines Sales Market Overview:

BCG Vaccines Sales is commercial and public sector distribution and revenue creation from the vaccines of Bacillus Calmette–Guérin (BCG) vaccine, which are mainly used to prevent tuberculosis (TB) and treat non-muscle invasive bladder cancer (NMIBC). Market encompasses the government's vaccination programs, hospital utilization and manufacturing, regulatory approval, global procurement, and regional sales through international health organizations such as the WHO, UNICEF, and PAHO. Growth in BCG vaccine sales market is increasing due to global TB and bladder cancer cases, extended vaccination programs and innovations in the recombinant BCG strains and regional manufacturing. For example, WHO estimated more than 10.3 million new TB cases globally in 2024, promoting continuous demand for extended BCG vaccination coverage, while North America has seen an increase in the use of BCG in the treatment of bladder cancer due to the ongoing decrease of its aging population and alternative remedies. Growth in technological progress such as VPM1002 such as rebuilding BCG strains and regional manufacturing hubs further intensified the expansion of the market.

Asia-Pacific region led the market in 2024 due to high TB prevalence, strong local manufacturing (eg, Serum Institute, Sinopharm) and strong public health programs. Key players of the BCG Vaccine Sales Market include Serum Institute of India, AJ Vaccines, Sinopharm, Merck & Co., and Bio-Manguinhos/Fiocruz, driven by their global scale, which pre-intensification and integration with public health systems.

In the BCG vaccine sales market, more than 65% of countries apply 0% tariffs to support public health, while the remaining typically impose low tariffs (1-5%). However, non-tariff barriers to which WHO prequalifications, customs obstacles, and cold chain certification, have increased. End users include national health ministries, global health organizations, hospitals, and cancer treatment centers that require safe, effective, and scalable vaccine solutions.To know about the Research Methodology   :- Request Free Sample Report

Global BCG Vaccines Sales Market Dynamics

Increasing TB Prevalence and Early Immunization Drive BCG Vaccine Growth

Bacillus Calmette–Guerin (BCG) vaccine is generally given to new born babies and up to six months old, but they can be vaccinated any time up to five years of age with a high incidence of TB. Tuberculosis is a severe infection, which damages the lungs and at times different parts of the body, for example, the joints, kidneys and bones. The BCG vaccine has existed for a long time and is a standout amongst the most broadly used of all conventional vaccines. The factors that drive the worldwide BCG vaccine market incorporate increment in the prevalence of tuberculosis, particularly in creating and undeveloped nations, and mechanical progression in the section of vaccine research. Nonetheless, symptoms of BCG vaccine and a worldwide lack of this vaccination hinder the development of the market.

Global BCG Vaccines Sales Market Segmentation

Based on drug type, the immune BCG segment accounted for the highest share in 2023 and is also the fastest growing segment growing at a CAGR of 4.9% during the BCG vaccines sales market forecast period. The factors contributing toward the growth of this segment include the role of BCG in effectively helping TB prevention and as of now, there is no substitute vaccine for immune BCG.

Based on Usage, the BCG Vaccines Sales Market is segmented into Tuberculosis and Bladder Cancer. Tuberculosis dominant segment in the BCG Vaccines Sales Market in 2024, accounting for the largest share due to its widespread use in national immunization programs, particularly in high TB-burden countries across Asia, Africa, and South America. The BCG vaccine has been a cornerstone of childhood TB prevention for decades, with the World Health Organization recommending it at birth in countries with high incidence. While BCG is increasingly used in treating non-muscle invasive bladder cancer (NMIBC), especially in developed regions, the volume and global reach of TB-related immunization far surpass oncology applications, making tuberculosis the leading usage category.

BCG Vaccines Sales Market Regional Insights:

From a geographical point of view, Asia-Pacific is expected to occupy more than two-thirds of the overall market shares by 2032, due to increased demand in low-level income population, i.e. India, to prevent tuberculosis epidemic. For now, the region of Latin America, the Middle East, and Africa (LAMEA) is predicted to grow at the highest CAGR of 5.3% due to increased awareness and higher disposable income of consumers.

The BCG Vaccines Sales Market Report contains in-depth analysis of major drivers, opportunities, challenges and their impact on the market. The BCG Vaccines Sales Market report also provides data about the government policies. Also provides detail information of BCG Vaccines. This research report also adds a snapshot of key competition, market trends during the forecast period, expected growth rates and the primary factors driving and impacting growth market data. This information will be beneficial or helpful to the decision makers.

The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding the Global BCG Vaccines Sales Market dynamics, structure by identifying and analysing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address questions of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the Global BCG Vaccines Sales Market.

BCG Vaccines Sales Market: Competitive Landscape

key players of BCG Vaccine Sales Market are Serum Institute of India, AJ Vaccines, Sinopharm, Merck & Co., and Bio-Manguinhos/Fiocruz, driven by their global scale, which pre-intensification and integration with public health systems. These companies are major global participants, reflecting industry-wide attention on extended vaccination coverage in both high-upper manufacturing, thermostable yogas, disease-specific BCG strains, and developing and developed fields. In addition, BB-NCIPD, BB-NCIPD, Biofabri, Butantan, IDT Biologika, and Haffkine are developing the target market through the development of BCG strands like BCG strands such as WHO-backed programs, regional vaccination participation, and VPM1002. The Serum Institute of India has reached an estimated USD 2.6 billion in 2024 revenue and maintains one of the largest global BCG capabilities, while Merck’s TICE BCG remains a major product for bladder cancer in North America despite recent deficiency. recombinant BCG strains such as technical promotion, WHO-backed procurement networks, and targeted regional production are re-shaping the competitive landscape, led by the global vaccine access with these firms.

Key Trends in the BCG Vaccines Sales Market:

• Dual-Use Expansion: TB & Bladder Cancer
Growing use of BCG vaccines beyond tuberculosis, especially in non-muscle invasive bladder cancer (NMIBC), is expanding demand in high-income regions like North America and Europe.

• Recombinant & Next-Gen BCG Development
Advancements in recombinant BCG strains (e.g., VPM1002) are driving innovation, aiming for better safety, efficacy, and stability, especially for immunocompromised patients.

• Global Supply Diversification & Local Manufacturing
Increasing reliance on regional public manufacturers and tech transfer initiatives is improving access and reducing dependency on a few global suppliers, particularly in Africa and South America.

Recent Developments in BCG Vaccines Sales Market:

BCG Vaccines Sales Market Scope: Inquire before buying

BCG Vaccines Sales Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

North America:

1. Intervax Ltd (Canada)
2. Merck & Company Inc (USA)
3. Sanofi S.A. – Regional Facility (France)
4. Bio Farma (USA)
5. GreenSignal USA – Regional Partner (USA)
6. Pfizer Inc. (USA)

Europe:

7. AJ Vaccines (Denmark)
8. Statens Serum Institute (Denmark)
9. BB-NCIPD Ltd. (Bulgaria)
10. Biofabri (Zendal Group) (Spain)
11. IDT Biologika (Germany)

Asia-Pacific:

12. China National Pharmaceutical Group – Sinopharm (China)
13. Shanghai Institute of Biological Products (China)
14. Serum Institute of India Pvt. Ltd. (India)
15. Greensignal Bio Pharma Limited (India)
16. Haffkine Bio-Pharmaceutical Corporation Ltd. (India)

South America

17. Bio-Manguinhos/Fiocruz (Brazil)
18. Instituto Butantan (Brazil)
19. ANLIS Malbrán (Argentina)
20. Sinergium Biotech (Argentina)
21. Instituto Nacional de Salud del Niño (Peru)

Frequently Asked Questions:

1. Which region has the largest share in Global BCG Vaccines Sales Market?
Ans: Asia-Pacific region held the highest share in 2024.

2. What is the growth rate of Global BCG Vaccines Sales Market?
Ans: The Global Market is growing at a CAGR of 4.2% during forecasting period 2025-2032.

3. What is scope of the Global BCG Vaccines Sales market report?
Ans: Global Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global BCG Vaccines Sales market?
Ans: The BCG Vaccine Sales Market key player are Serum Institute of India, AJ Vaccines, Sinopharm, Merck & Co., and Bio-Manguinhos/Fiocruz.

5. What was the Global BCG Vaccines Sales Market size in 2024?
Ans: The Global BCG Vaccines Sales Market size was USD 101.30 Million in 2024.